Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma
Yıl: 2021 Cilt: 38 Sayı: 3 Sayfa Aralığı: 204 - 210 Metin Dili: İngilizce DOI: 10.4274/tjh.galenos.2020.2020.0409 İndeks Tarihi: 25-05-2022
Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma
Öz: Objective: Autologous stem cell transplantation (ASCT) is a significant
and potentially curative treatment modality for patients with
relapsed/refractory lymphoma. Insufficient mobilization and harvest
of peripheral stem cells can be a major obstacle for performing ASCT.
The aim of this study was to evaluate the factors that might influence
mobilization failure in patients with lymphoma.
Materials and Methods: Eighty-seven patients diagnosed with
non-Hodgkin and Hodgkin lymphoma who underwent stem cell
mobilization afterwards at the Hacettepe University Medical School
Bone Marrow Transplantation Center, Turkey, between the years of
2000 and 2018 were evaluated.
Results: A total of 87 patients were included in this study. In 66 of 87
patients (75.9%), the first mobilization trial was successful. Adequate
(≥2x106/kg) CD34+ cells were collected in the first apheresis for 66
patients (9.5±8.1). For 21 of 87 (24.1%), the first mobilization trial was
unsuccessful. Therefore, a second mobilization trial was performed for
these patients with plerixafor (5.5±3.3). The number of CD34+ cells
was significantly higher in patients who were successful in the first
mobilization (p=0.002).
Conclusion: The success rate of the first mobilization trial was found
to be higher in patients with high platelet counts before mobilization
and patients who received chemotherapy-based mobilization
protocols. In the patients who had mobilization failure in the first
trial, plerixafor was used in a later mobilization, and those patients
had an adequate amount of stem cells for ASCT. Parameters predicting
mobilization failure would allow for preemptive, more cost-effective
use of such agents during the first mobilization attempt; however, risk
factors for mobilization failure are still not clea
Anahtar Kelime: Hodgkin ve Non-Hodgkin Lenfomalı Hastalarda Kök Hücre Mobilizasyon Başarısızlığının Öngörüsü
Öz: Amaç: Otolog kök hücre transplantasyonu (OKHT), relaps/refrakter
lenfoma hastaları için önemli ve potansiyel olarak küratif bir
tedavi yöntemidir. Yetersiz mobilizasyon ve periferik kök hücrelerin
toplanması OKHT’nin gerçekleştirilmesi için büyük bir engel olabilir.
Bu çalışmanın amacı lenfoma hastalarında mobilizasyon başarısızlığını
etkileyebilecek faktörleri değerlendirmektir.
Gereç ve Yöntemler: Hacettepe Üniversitesi Tıp Fakültesi Kemik İliği
Nakil Merkezi’nde 2000-2018 yılları arasında Hodgkin ve non-Hodgkin
lenfoma tanısı alan ve sonrasında kök hücre mobilizasyonu yapılan 87
hasta değerlendirildi.
Bulgular: Bu çalışmaya toplam 87 hasta dahil edildi. Seksen yedi
hastanın 66’sında (%75,9) ilk mobilizasyon denemesi başarılı oldu.
66 hastada (9,5±8,1) ilk aferezde yeterli (≥2x106/kg) CD34+ hücre
toplandı. Seksen yedi kişiden 21’i (%24,1) için ilk mobilizasyon
denemesi başarısız oldu. Bu nedenle bu hastalara pleriksafor ile
(5,5±3,3) ikinci bir mobilizasyon denemesi yapıldı. İlk mobilizasyonda
başarılı olan hastalarda CD34+ hücre sayısı anlamlı olarak yüksekti
(p=0,002).
Sonuç: Mobilizasyon öncesi trombosit sayısı yüksek olan hastalarda
ve kemoterapi bazlı mobilizasyon protokolleri alan hastalarda ilk
mobilizasyon denemesinin başarı oranı daha yüksek bulundu. İlk
denemede mobilizasyon başarısızlığı olan hastalarda daha sonraki
mobilizasyonda pleri ksafor kullanılmış ve bu hastalarda OKHT için
yeterli miktarda kök hücre mevcuttu. Mobilizasyon başarısızlığını
öngören parametreler, ilk mobilizasyon girişimi sırasında bu tür
ajanların önleyici, daha uygun maliyetli kullanımına izin verecektir;
ancak, mobilizasyon başarısızlığı için risk faktörleri hala net değildi
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Sheppard D, Bredeson C, Allan D, Tay J. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2012;18:1191-1203.
- 2. Van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, Schouten HC. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. J Clin Apher 2017;32:295-301.
- 3. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18:1360-1377.
- 4. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011;118:4530-4540.
- 5. Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH. Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:967-972.
- 6. Mendrone A Jr, Arrais CA, Saboya R, de Alencar Fischer Chamone D, Dulley FL. Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients. Transfus Apher Sci 2008;39:187-192.
- 7. Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 2004;33:907-912.
- 8. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol1982;5:649-656.
- 9. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin’s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-3068.
- 10. Ford C, Chan K, Reilly W, Petersen F. An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors. Transfusion 2003;43:622-625.
- 11. Milone G, Tripepi G, Martino M, Ancora F, Bartolozzi B, Spadaro A, Nozzoli C, La Fauci A, Amico I, Leotta S, Poidomani M, Irrera G, Iacopino P, Saccardi R, Guidi S, Bosi A. Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding “on demand” use of plerixafor. Blood Transfus 2013;11:94-101.
- 12. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009;84:335-337.
- 13. Rossi G, Skert C, Morello E, Almici C, Arcaini L, Basilico C, Cavalli L, Botto B, Castelli A, Pica G, Ripamonti F, Salvi F, Carella AM, Gaidano G, Levis A, Nosari A, Russo D, Vitolo U. PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization. Hematol Oncol 2015;33:125-132.
- 14. 14. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, Goldschmidt H, Ho AD. Poor mobilization of hematopoietic stem cells— definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010;16:490-499.
- 15. Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omede P, Bondesan P, Magni M, Matteucci P, Gallamini A, Pileri A, Gianni AM. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant 2002;30:725-732.
- 16. Özkurt ZN, Yeğin ZA, Suyanı E, Akı ŞZ, Acar K, Yağcı M, Türköz Sucak G. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. J Clin Apher 2010;25:280-286.
- 17. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-1056.
- 18. Fruehauf S, Seggewiss R. It’s moving day: factors affecting peripheral blood stem mobilization and strategies for improvement. Br J Haematol 2003;122:360-375.
- 19. André M, Baudoux E, Bron D, Canon JL, D’Hondt V, Fassotte MF, D’Hondt L, Fillet G, Humblet Y, Jerusalem G, Vermeulen P, Symann M, Beguin Y. Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003;43:50-57.
| APA | Demiroglu H, Çiftçiler R, BÜYÜKAŞIK Y, GOKER A (2021). Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma. , 204 - 210. 10.4274/tjh.galenos.2020.2020.0409 |
| Chicago | Demiroglu Haluk,Çiftçiler Rafiye,BÜYÜKAŞIK Yahya,GOKER ALI HAKAN Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma. (2021): 204 - 210. 10.4274/tjh.galenos.2020.2020.0409 |
| MLA | Demiroglu Haluk,Çiftçiler Rafiye,BÜYÜKAŞIK Yahya,GOKER ALI HAKAN Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma. , 2021, ss.204 - 210. 10.4274/tjh.galenos.2020.2020.0409 |
| AMA | Demiroglu H,Çiftçiler R,BÜYÜKAŞIK Y,GOKER A Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma. . 2021; 204 - 210. 10.4274/tjh.galenos.2020.2020.0409 |
| Vancouver | Demiroglu H,Çiftçiler R,BÜYÜKAŞIK Y,GOKER A Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma. . 2021; 204 - 210. 10.4274/tjh.galenos.2020.2020.0409 |
| IEEE | Demiroglu H,Çiftçiler R,BÜYÜKAŞIK Y,GOKER A "Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma." , ss.204 - 210, 2021. 10.4274/tjh.galenos.2020.2020.0409 |
| ISNAD | Demiroglu, Haluk vd. "Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma". (2021), 204-210. https://doi.org/10.4274/tjh.galenos.2020.2020.0409 |
| APA | Demiroglu H, Çiftçiler R, BÜYÜKAŞIK Y, GOKER A (2021). Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma. Turkish Journal of Hematology, 38(3), 204 - 210. 10.4274/tjh.galenos.2020.2020.0409 |
| Chicago | Demiroglu Haluk,Çiftçiler Rafiye,BÜYÜKAŞIK Yahya,GOKER ALI HAKAN Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma. Turkish Journal of Hematology 38, no.3 (2021): 204 - 210. 10.4274/tjh.galenos.2020.2020.0409 |
| MLA | Demiroglu Haluk,Çiftçiler Rafiye,BÜYÜKAŞIK Yahya,GOKER ALI HAKAN Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma. Turkish Journal of Hematology, vol.38, no.3, 2021, ss.204 - 210. 10.4274/tjh.galenos.2020.2020.0409 |
| AMA | Demiroglu H,Çiftçiler R,BÜYÜKAŞIK Y,GOKER A Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma. Turkish Journal of Hematology. 2021; 38(3): 204 - 210. 10.4274/tjh.galenos.2020.2020.0409 |
| Vancouver | Demiroglu H,Çiftçiler R,BÜYÜKAŞIK Y,GOKER A Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma. Turkish Journal of Hematology. 2021; 38(3): 204 - 210. 10.4274/tjh.galenos.2020.2020.0409 |
| IEEE | Demiroglu H,Çiftçiler R,BÜYÜKAŞIK Y,GOKER A "Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma." Turkish Journal of Hematology, 38, ss.204 - 210, 2021. 10.4274/tjh.galenos.2020.2020.0409 |
| ISNAD | Demiroglu, Haluk vd. "Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma". Turkish Journal of Hematology 38/3 (2021), 204-210. https://doi.org/10.4274/tjh.galenos.2020.2020.0409 |
